STOCK TITAN

Klaviyo (NYSE: KVYO) director shifts 16,775 shares from Series B to A

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Klaviyo, Inc. director Roxanne Oulman reported a class-for-class conversion on July 22, 2026, in which the Roxanne Oulman 2025 GRAT converted 16,775 shares of Series B Common Stock into the same number of Series A shares. After this, the GRAT indirectly holds 29,891 Series B and 16,775 Series A shares. Oulman also reports direct positions of 15,165 Series B and Series A-related holdings totaling 37,343 shares/units, consisting of 22,521 Series A shares and 14,822 unvested restricted stock units. She disclaims beneficial ownership of the GRAT-held shares except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Oulman Roxanne
Role Director
Type Security Shares Price Value
Conversion Series B Common Stock F1, F2 16,775 $0.00 $0.00
Conversion Series A Common Stock F1, F2 16,775 -- --
holding Series B Common Stock F1 -- -- --
holding Series A Common Stock F3 -- -- --
Holdings After Transaction: Series B Common Stock — 29,891 shares (Indirect, By Roxanne Oulman 2025 GRAT); Series A Common Stock — 16,775 shares (Indirect, By Roxanne Oulman 2025 GRAT); Series B Common Stock — 15,165 shares (Direct); Series A Common Stock — 37,343 shares (Direct)
Footnotes (3)
  1. F1. Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
  2. F2. Shares held by Roxanne Oulman 2025 GRAT, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
  3. F3. Consists of (i) 22,521 shares of Series A Common Stock and (ii) 14,822 unvested restricted stock units awarded under the Issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement.
Shares converted 16,775 shares Series B Common Stock converted into Series A Common Stock on July 22, 2026
Indirect Series B via GRAT 29,891 shares Series B Common Stock indirectly held by Roxanne Oulman 2025 GRAT after conversion
Indirect Series A via GRAT 16,775 shares Series A Common Stock indirectly held by Roxanne Oulman 2025 GRAT after conversion
Direct Series B holdings 15,165 shares Series B Common Stock directly held, convertible into Series A on a 1:1 basis
Direct Series A shares and RSUs 37,343 shares/units Consists of 22,521 Series A shares and 14,822 unvested restricted stock units
Unvested restricted stock units 14,822 units RSUs each representing the contingent right to receive one Series A share upon vesting
Series B Common Stock financial
"Each share of the Issuer's Series B Common Stock is convertible into Series A"
Series A Common Stock financial
"Convertible at any time into one share of the Issuer's Series A Common Stock"
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
restricted stock units financial
"Includes 14,822 unvested restricted stock units under the 2023 Stock Option and Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
GRAT financial
"Shares held by Roxanne Oulman 2025 GRAT, of which the Reporting Person serves as trustee"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider share conversion did Roxanne Oulman report for Klaviyo (KVYO)?

Roxanne Oulman reported that the Roxanne Oulman 2025 GRAT converted 16,775 shares of Series B into Series A Common Stock on July 22, 2026. This reflects a class-for-class conversion within Klaviyo, Inc., rather than an open-market purchase or sale.

How many Klaviyo (KVYO) shares does the 2025 GRAT hold after the transaction?

After the conversion, the 2025 GRAT indirectly holds 29,891 shares of Klaviyo Series B Common Stock and 16,775 shares of Series A Common Stock. These holdings are reported as indirect, with Oulman serving as trustee and providing a pecuniary-interest-based ownership disclaimer.

What direct Klaviyo (KVYO) holdings does director Roxanne Oulman report?

Oulman reports direct holdings of 15,165 shares of Klaviyo Series B Common Stock and Series A-related holdings totaling 37,343 shares/units. The 37,343 figure consists of 22,521 Series A shares and 14,822 unvested restricted stock units awarded under Klaviyo’s 2023 equity plan.

Are the GRAT-held Klaviyo (KVYO) shares fully beneficially owned by Roxanne Oulman?

No. The filing states that shares held by the Roxanne Oulman 2025 GRAT are reported indirectly, and Oulman disclaims Section 16 beneficial ownership of those shares except to the extent of her pecuniary interest, if any, as trustee of the GRAT.

Was Roxanne Oulman’s Klaviyo (KVYO) conversion under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 trading plan checkbox was not marked and the footnotes do not describe any such plan. Accordingly, the reported share conversion is not described as occurring pursuant to a pre-arranged Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oulman Roxanne

(Last)(First)(Middle)
C/O KLAVIYO, INC.
125 SUMMER STREET, 6TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Klaviyo, Inc. [ KVYO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Series A Common Stock07/22/2026C16,775A(1)16,775IBy Roxanne Oulman 2025 GRAT(2)
Series A Common Stock37,343(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series B Common Stock(1)07/22/2026C16,775 (1) (1)Series A Common Stock16,775$029,891IBy Roxanne Oulman 2025 GRAT(2)
Series B Common Stock(1) (1) (1)Series A Common Stock15,16515,165D
Explanation of Responses:
1. Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
2. Shares held by Roxanne Oulman 2025 GRAT, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
3. Consists of (i) 22,521 shares of Series A Common Stock and (ii) 14,822 unvested restricted stock units awarded under the Issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement.
Remarks:
/s/ Landon Edmond, Attorney-in-Fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)